Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 29.11% | 10.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.11% | 10.30% | |||
| Cost of Revenue | -31.75% | 159.25% | |||
| Gross Profit | 35.89% | 3.66% | |||
| SG&A Expenses | 5.76% | 24.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.16% | 29.55% | |||
| Operating Income | 93.08% | -238.12% | |||
| Income Before Tax | 79.76% | -170.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 79.76% | -170.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 79.76% | -170.56% | |||
| EBIT | 93.08% | -238.12% | |||
| EBITDA | 93.98% | -246.16% | |||
| EPS Basic | 79.89% | -169.91% | |||
| Normalized Basic EPS | 79.92% | -169.70% | |||
| EPS Diluted | 79.89% | -169.91% | |||
| Normalized Diluted EPS | 79.92% | -169.70% | |||
| Average Basic Shares Outstanding | 0.81% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.81% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||